Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Veronika Eder, Magdalena Benda, Helmut Pürerfellner(Krankenhaus der Elisabethinen), W. Schuyler Jones(Duke University), Stefan Stojković, Manesh R. Patel(Clinical Research Institute), Miriam Eber, Beatrix Mutschlechner, Peter Jirak(Paracelsus Medical University), Valeria Caso, Tobias Kolbitsch, Michael Derndorfer, Hardi Mundl(Roche (Switzerland)), Matthias Frick, Wilfried Schgoer, Lukas Sprenger, Christopher Adlbrecht, Alexandra Schratter, Maximilian Mächler, Keith A.A. Fox(University of Edinburgh), Uta C. Hoppe(Baker Heart and Diabetes Institute), Diana A. Gorog(University of Hertfordshire), Robert Schönbauer(Leipzig Heart Institute), Christoph Keil(Bayer (Germany)), Christoph Neumann(Bayer (Germany)), Johann Auer, Christian Ebner(University of Chicago), Martin Manninger-Wünscher, Thomas Viethen(Bayer (Germany)), Johannes Hajos, Jutta Bergler‐Klein, Markus Stühlinger(Innsbruck Medical University), Stuart J. Connolly(Population Health Research Institute), Ursula Rohrer, Jonas Oldgren, Václav Durdil(University Hospital in Motol), Michael Lichtenauer(Medical University of Vienna), Andreas Schober(Ludwig-Maximilians-Universität München), Dietmar Reitgruber, Eva Preishuber, Florian Schmalzer, Carina Primus-Grabscheit, Sead Pandzic, Martin Hubauer, Christoph H. Saely(Bayer (Germany)), Moritz Mirna(Paracelsus Medical University), Jana M. Schwarzl, Christian Hengstenberg(Medical University of Vienna)
The Lancet
April 1, 2022
Cited by 310


Related Papers